



Long-term dupilumab therapy reduces concomitant medication use in patients with CRSwNP

Study design



Retrospective, real-world cohort; repeated measurements at each visit

Concomitant medications tracked



Mean concomitant medications at baseline: **1.6/patient**


PROM Trajectories

SNOT-22	↓
TNSS	↓
ACT	↑
MINI-AQLQ	↑

Concomitant medication trajectories

All	↓
INCS	↓
Asthma medications	↓
Other (antihistamines etc.)	↓

Trajectories of concomitant medications



Dupilumab reduces concomitant medication demand and improves disease control in CRSwNP & Asthma